+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Human Insulin Market - Growth, Trends, and Forecast (2012 - 2024)

  • ID: 4591712
  • Report
  • Region: North America, United States
  • 75 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2019
1 of 4

FEATURED COMPANIES

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • MORE
Market Overview

The North American human insulin market is expected to register a CAGR of 5.64% during the forecast period of 2019 - 2024, and the market is estimated to reach a value of USD 11.6 billion by 2019.

Diabetes ranks among the fast-growing chronic diseases in the North American region, especially in the United States. Genetic factor is one of the major reasons for the rapid spread of the disease. Sedentary lifestyles and obesity are the other factors responsible for the high prevalence of the disease.

Although insulin has been used for the treatment of diabetes for over 90 years, more than half of those who need insulin today still cannot afford and access it due to the high cost of the product.

Scope of the Report

The North America human insulin market is segmented by product type (basal or long-acting insulin, bolus or fast-acting insulin, traditional human insulin, combination insulin, and biosimilar insulin) and geography.

Key Market Trends - The United States Dominates the Market

Among the North American countries, the United States dominates around 95% of the total insulin market in the region. This is mainly due to the high diabetes prevalence in the country.

The United States records the highest healthcare expenditure globally, and it also has the higher adoption of advanced therapeutics.

The market size of the insulin market in 2017 was USD 10.6 billion, and the market is expected to record a CAGR of 5.5% during the forecast period (2019-2024).

Lantus occupied the largest market share in 2017. However, the product is expected to decrease during the forecast period, due to similar insulin glargines present in the market, like Toujeo and Basaglar.

Toujeo is the brand of Sanofi that is an upgraded version of Lantus and acts for more than 30 hours. Basaglar is the biosimilar of Lantus. However, the product was approved as a follow-on biologics in the United States.

Increasing Pricing Pressure

The United States is the primary market for all the insulin manufacturers, since the revenue from the country alone accounts to approximately more than 50%, globally.

Pharmaceutical companies have increased the price of insulin drugs since the past few years, owing to increased US payer pressure.

Due to the high prevalence of diabetes, the number of patients relying on insulin are growing, due to which there is a high demand for insulin production in volume.

Insulin is manufactured through sophisticated r-DNA technology, due to which there are very few companies in the market that produce insulin.

Thus, there is very high competition between these manufacturers who always strive to meet the patient needs. With deductibles far outpacing income, insulin has become unaffordable even for well-off US citizens.

Competitive Landscape

The North American human insulin market is highly fragmented, with three major manufacturers having a large market share. In the United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. While in the remaining countries, the manufacturers confine to the other local or region-specific manufacturers.

Mergers and acquisitions that happened between the players in the recent past helped the companies to strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Insulin (Value and Volume 2012-2024)
5.1.1.1 Basal or Long-acting Insulin
5.1.1.1.1 Lantus (Insulin Glargine)
5.1.1.1.2 Levemir (Insulin Detemir)
5.1.1.1.3 Toujeo (Insulin Glargine)
5.1.1.1.4 Tresiba (Insulin Degludec)
5.1.1.1.5 Basaglar (Insulin Glargine)
5.1.1.2 Bolus or Fast-acting Insulin
5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.1.2.2 Humalog (Insulin Lispro)
5.1.1.2.3 Apidra (Insulin Glulisine)
5.1.1.3 Traditional Human Insulin
5.1.1.3.1 Novolin/Actrapid/Insulatard
5.1.1.3.2 Humulin
5.1.1.3.3 Insuman
5.1.1.4 Combination Insulin
5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)
5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)
5.1.1.5 Biosimilar Insulin
5.1.1.5.1 Insulin Glargine Biosimilars
5.1.1.5.2 Human Insulin Biosimilars
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume 2012-2024)
5.2.1.1.1 Basal or Long-acting Insulin
5.2.1.1.2 Bolus or Fast-acting Insulin
5.2.1.1.3 Traditional Human Insulin
5.2.1.1.4 Combination Insulin
5.2.1.1.5 Biosimilar Insulin
5.2.1.1.6 By Company (Novo Nordisk, Sanofi, Eli Lilly and others)
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 Basal or Long-acting Insulin
5.2.1.2.2 Bolus or Fast-acting Insulin
5.2.1.2.3 Traditional Human Insulin
5.2.1.2.4 Combination Insulin
5.2.1.2.5 Biosimilar Insulin
5.2.1.2.6 By Company (Novo Nordisk, Sanofi, Eli Lilly and others)
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 Basal or Long-acting Insulin
5.2.1.3.2 Bolus or Fast-acting Insulin
5.2.1.3.3 Traditional Human Insulin
5.2.1.3.4 Combination Insulin
5.2.1.3.5 Biosimilar Insulin
5.2.1.3.6 By Company (Novo Nordisk, Sanofi, Eli Lilly and others)

6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2013-2024)
6.2 Type 2 Diabetes Population (2013-2024)

7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novo Nordisk
  • Sanofi
  • Eli Lilly
Note: Product cover images may vary from those shown
Adroll
adroll